fordham financial thinkequity

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager. The Company is led by its Chairman, Thomas Finke (former Chairman and CEO of Barings LLC), its CEO and director, Martin A. Sumichrast (Co-CEO of cbdMD, Inc.), and its director, W. Tom Donaldson (founder of Blystone & Donaldson). By John George – Senior Reporter, Philadelphia Business Journal 333-249636) relating to the shares was filed with the U.S. Securities and Exchange Commission (“SEC”), which became effective on February 9, 2021. The Company’s sponsor, Adara Sponsor LLC, is led by cbdMD, Inc. (NYSE American: YCBD, YCBDpA) and Blystone & Donaldson, LLC. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the SEC. Forward Looking Statements. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a public offering price of $8.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts, commissions and offering expenses. #UNRIG Video (43:11) Wall Street Financial Crime — $100 Trillion Stolen from Main Street — Appeal to President Trump; Tweet: Marc Cohodes Weaves His Web — NewsFlash — We Have It All, Marc! This offering is being made only by means of a prospectus. The units will be listed on the NYSE American stock exchange (“NYSE American”) and trade under the ticker symbol “ADRA.U” beginning February 9, 2021. Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 337,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager. ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING. The DeCarley Perspective and The Financial Futures ... Needham & Company and ThinkEquity 333-234292) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on February 23, 2021. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Fordham Financial A Full-Service Investment Bank ThinkEquity is a boutique investment bank created by experienced professionals that have worked together for over a decade, collectively financing over $50 billion of public and private capital raises, restructurings, and mergers and acquisitions. Release: President Trump Briefed on NSA Capabilities Against Financial Crime #UNRIG Video (29:36) Dave Hodges Interviews Robert Steele on Trump Triumphs Against Wall Street, Democrats, Satanists Release: President Trump Urged to Create DoD-DoJ Task Force on Financial Crime ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. A registration statement on Form F-1 (File No. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Loeb & Loeb LLP serving as Underwriter’s Counsel. Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Opt-into our eNewsletter NOW! Copies of the final prospectus, when available, may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., at 17 State … Kevin is a graduate of Fordham University where he studied International Political Economy and English. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. The shares are expected to begin trading on The Nasdaq Capital Market on February 10, 2021 under the ticker symbol “VLON.” The offering is expected to close on February 12, 2021, subject to satisfaction of customary closing conditions. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. In addition to Messrs. Finke, Sumichrast and Donaldson, the Company’s Board of Directors also include Frank Quintero, Dylan Glenn and Beatriz Acevedo-Greiff. For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more! Investor Contact:JTC Team, LLC Jenene Thomas (833) 475-8247 vallon@jtcir.com. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy. (704) 249-9515, Titan Medical Announces Filing of Preliminary Short Form Prospectus, Whiting USA Trust II Announces Trust Quarterly Results. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on February 8, 2021. Lawyer: James “Wes” Christian; Subject: Jon Yalmokas; Subject: Justin Lubell Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. © 2021 GlobeNewswire, Inc. All Rights Reserved. ADARA ACQUISITION CORP. John.Weston@cbdMD.com Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Director of Investor Relations Copies of these documents are available on the SEC’s website, www.sec.gov. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. John Weston ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on the NYSE American under the symbols “ADRA” and “ADRA.WS,” respectively. Only whole warrants are exercisable and will trade. ThinkEquity, a division of Fordham Financial Management, Inc., is serving as sole book-running manager for the offering. Copies of the final prospectus, when available, may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., at 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at prospectus@think-equity.com. Adara Acquisition Corp. (the “Company”), a newly incorporated blank check company, today announced the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. Please replace the release with the following corrected version due to multiple revisions. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. WithumSmith+Brown, PC serves as auditor. While the Company may pursue an initial business combination target in any industry, it currently intends to concentrate its search for a target business operating in the consumer products and related industries. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005877/en/, cbdMD, Inc. ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering. A registration statement on Form S-1 (File No. The Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 units at the initial public offering price to cover over-allotments, if any. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Continental Stock Transfer & Trust Company is acting as trustee. https://www.businesswire.com/news/home/20210208005877/en/, Tweets by financialbuzz.